Zobrazeno 1 - 10
of 1 228
pro vyhledávání: ''
Autor:
Atsushi Naganuma, Takaaki Tanaka, Atsushi Hiraoka, Satoshi Yasuda, Kazuya Kariyama, Noritomo Shimada, Shinichiro Nakamura, Satoru Kakizaki, Michitaka Imai, Koichi Takaguchi, Takuya Nagano, Toshifumi Tada, Akemi Tsutsui, Takashi Kumada, Takeshi Hatanaka, Kazuhiro Nouso, Toru Ishikawa, Kunihiko Tsuji, Hidenori Toyoda, Hiroshi Shibata, Ei Itobayashi
Publikováno v:
Oncology
Background/Aim: With the development of systemic treatment methods for unresectable hepatocellular carcinoma (uHCC), the concept of unsuitable for transcatheter arterial chemoembolization (TACE) has become important. This study aimed to establish a s
Autor:
Ines Beilmann-Lehtonen, Ulf-Håkan Stenman, Caj Haglund, Tuomas Kaprio, Kajsa Björkman, Camilla Böckelman
Publikováno v:
Oncology. 100:22-30
Objectives: Colorectal cancer is the third most common cancer worldwide, with an obvious need for more accurate prognostics. Previous studies identified C-reactive protein (CRP) as a prognostic serum biomarker for colorectal cancer, whereas the bioma
Autor:
Mariko Kobayashi, Satoshi Saitoh, Nozomu Muraishi, Masahiro Kobayashi, Fumitaka Suzuki, Kenji Ikeda, Norio Akuta, Yasuji Arase, Shunichiro Fujiyama, Hiromitsu Kumada, Tetsuya Hosaka, Hitomi Sezaki, Yusuke Kawamura, Yoshiyuki Suzuki
Publikováno v:
Oncology
Introduction: It is unclear whether the relationships between changes in fibrosis and circulating microRNA-122 (miR-122) dynamics might influence the prognosis of nonalcoholic fatty liver disease (NAFLD). Methods: This study investigates the impact o
Autor:
Jan-Peter Roth, Francesco Vitali, Dagmar Busse, W Schreiner, Susanne Merkel, Robert Stoehr, Arndt Hartmann, Markus Eckstein, Axel Wein, Stephan Kersting, Michael Uder, Peter Anhut, Robert Grützmann, Jürgen Siebler, Nicola Ostermeier, Markus F. Neurath, Kerstin Wolff, Clemens Neufert
Publikováno v:
Oncology. 100:1-11
Objective: The study aimed to prospectively evaluate a new molecular biomarker panel (KRAS, NRAS, BRAF, PIK3CA, and ERBB2) for palliative first-line treatment of colorectal cancer (CRC), including a multidisciplinary treatment approach. The rate of s
Autor:
Alla Berlin, Leora Brazg Ferro, Ester Osher, Orit Gutfeld, Inbal Golomb, Inna Ospovat, Viacheslav Soyfer, Ido Wolf, Shira Peleg Hasson
Publikováno v:
Oncology. 99:373-379
Introduction: Extrapulmonary small-cell cancer (EPSCC) is a relatively rare malignancy. The management of EPSCC is usually extrapolated from small-cell lung cancer (SCLC). In spite of the morphological similarity of the 2 malignancies, there are many
Autor:
Thomas Wolfram Paul Friedl, Wolfgang Janni, Davut Dayan, Amelie de Gregorio, Jens Huober, Nikolaus de Gregorio, Eva Hering, Peter Widschwendter, Inga Bekes
Publikováno v:
Oncology. 99:780-789
Introduction: Ki67 as a proliferative marker has prognostic and therapeutic relevance in early breast cancer (EBC). However, standard cutoffs for distinguishing low and high Ki67 do not exist. Material and Methods: Data from all patients treated at t
Autor:
Kotaro Yamashita, Makoto Yamasaki, Hidetoshi Eguchi, Yuichiro Doki, Tomoki Makino, Kiyokazu Nakajima, Takuro Saito, Norihiro Matsuura, Yukinori Kurokawa, Tsuyoshi Takahashi, Koji Tanaka, Yutaka Kimura, Masaaki Motoori, Kazuyoshi Yamamoto
Publikováno v:
Oncology. 99:547-554
Purpose: Esophageal cancer patients may simultaneously have resectable esophageal cancer and undiagnosable incidental minute solid pulmonary nodules. While the latter is rarely metastatic, only a few studies have reported on the outcomes of such nodu
Autor:
Hiroaki Motoyama, Hikaru Hayashi, Kentaro Fukushima, Yuji Soejima, Shinsuke Sugenoya, Koji Kubota, Kiyotaka Hosoda, Koya Yasukawa, Akira Shimizu, Ryoichiro Kobayashi, Tsuyoshi Notake
Publikováno v:
Oncology. 99:703-712
Introduction: The usefulness of adjuvant chemotherapy in biliary tract cancer (BTC) is poorly reported. This study aimed to evaluate the effectiveness and safety of adjuvant gemcitabine plus S-1 (GS) chemotherapy after curative surgical resection for
Autor:
Javier Martin Broto, Robin L. Jones
Publikováno v:
Oncology. 99:8-16
In the first-line setting of advanced soft tissue sarcomas (STS), the treatment aim generally drives decision-making. Anthracycline combinations with ifosfamide or dacarbazine are more appropriate when the aim is tumour shrinkage, and doxorubicin mon
Autor:
Naoki Kamachi, Masahito Nakano, Takashi Niizeki, Takumi Kawaguchi, Takuji Torimura, Shigeo Shimose, Hironori Koga, Yu Noda, Ryoko Kuromatsu, Masatoshi Tanaka, Tomotake Shirono, Shusuke Okamura, Hideki Iwamoto, Akira Kajiwara
Publikováno v:
Oncology. 99:756-765
Background & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate